RASD2 Drives Renal Clear Cell Carcinoma Progression via RAF1 (Ser338) Phosphorylation [0.03%]
RASD2通过RAF1(Ser338)磷酸化驱动肾透明细胞癌进展
Jingxuan Yu,Gang Yu,Yuan Liu et al.
Jingxuan Yu et al.
Clear cell renal cell carcinoma (ccRCC) is a highly aggressive malignancy with limited treatment options. Although RASD2, which encodes a Ras-related GTP-binding protein, has been linked to melanoma progression, its role in ccRCC remains un...
Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model [0.03%]
在同基因EGFR突变型肺癌小鼠模型中,达菲替尼通过EGFR V804F突变克服奥希替尼耐药性
Takaaki Tanaka,Masato Fujitani,Masataka Taoka et al.
Takaaki Tanaka et al.
Osimertinib is the standard first-line treatment for advanced EGFR-mutant non-small cell lung cancer. However, acquired resistance invariably develops, and identifying novel resistance pathways is clinically important as a substantial porti...
Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development [0.03%]
针对癌症的细胞周期弱点:治疗发展的新兴策略
Nana Kamakura,Minji Jo,Motoko Takahashi et al.
Nana Kamakura et al.
Cell division is a fundamental cellular process that ensures propagation of genetic material to daughter cells. This process relies on the fidelity of DNA replication and chromosome segregation and is primarily regulated by sequential activ...
Organ-Specific Cancer-Associated Fibroblast Subtypes Across the Digestive System Linked to Cancer Hallmarks [0.03%]
贯穿消化系统的器官特异性癌相关成纤维母细胞亚型与癌症标志物有关
Huaitao Wang,Takashi Semba,Atsuko Yonemura et al.
Huaitao Wang et al.
Cancer-associated fibroblasts (CAFs) are major stromal components of the tumor microenvironment (TME) and play diverse roles in gastrointestinal (GI) cancer progression, immunity, and therapeutic resistance. However, the heterogeneity, tiss...
Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes [0.03%]
针对少见EGFR突变非小细胞肺癌患者,阿法替尼与奥希替尼真实世界疗效比较研究
Yutaro Nagano,Hiroshi Yokouchi,Ryota Saito et al.
Yutaro Nagano et al.
Non-small cell lung cancers (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations (UMs) are clinically heterogeneous, and the optimal first-line EGFR tyrosine kinase inhibitor (EGFR-TKI), as well as the role of subseq...
Interpreting Early-Onset Colorectal Cancer in Japan: A Descriptive Epidemiologic Review Using Public Summary Statistics [0.03%]
日本早期结直肠癌的流行病学特征描述性研究综述
Keitaro Matsuo,Hidemi Ito
Keitaro Matsuo
Early-onset colorectal cancer (EOCRC) is increasingly described as a rising disease entity, but the descriptive epidemiologic conditions required to interpret that rise remain incompletely articulated. Using Japanese public summary statisti...
Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3 [0.03%]
致癌BRAF和KRAS通过调节TET3促进DNA脱甲基化
Ichiro Onoyama,W Rod Hardy,Shoichiro Takeishi et al.
Ichiro Onoyama et al.
Aberrant epigenetic modification is one of the characteristics of the cancer genome. DNA hypermethylation of cytosine-phospho-guanine (CpG) islands, a hallmark of cancer cells, is well-studied and contributes to cancer development by silenc...
Gasdermin-Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer [0.03%]
Gasdermin介导的焦亡:对抗结直肠癌的新策略
Kaibo Guo,Yuqian Feng,Jiamin Lu et al.
Kaibo Guo et al.
Pyroptosis, a form of programmed cell death mediated by gasdermin proteins, has gained attention for its dual role in colorectal cancer (CRC) progression and therapy. While chronic pyroptosis-driven inflammation can promote tumorigenesis, a...
Evolving Pathology of Anaplastic Thyroid Carcinoma: Integrating Morphology, Immunohistochemistry, and Molecular Insights [0.03%]
甲状腺弥漫性癌的病理演变:形态学、免疫组织化学和分子见解的整合
Toru Odate,Tetsuo Kondo
Toru Odate
Anaplastic thyroid carcinoma (ATC) is a rare malignancy characterized by an extremely aggressive clinical course, in contrast to the typically indolent behavior of most thyroid carcinomas. Recent advances in high-throughput sequencing techn...
First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck [0.03%]
头颈部鳞状细胞癌和尿路上皮癌接受E7130首次人体剂量扩展研究试验的I期临床报告
Nobuaki Matsubara,Ken Saijo,Yasushi Shimizu et al.
Nobuaki Matsubara et al.
The dose escalation part of the first-in-human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose (RP2D) of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/prelimin...